Related Experiment Video

Updated: Jun 8, 2026

Modeling Spontaneous Metastatic Renal Cell Carcinoma (mRCC) in Mice Following Nephrectomy
11:27

Modeling Spontaneous Metastatic Renal Cell Carcinoma (mRCC) in Mice Following Nephrectomy

Published on: April 29, 2014

AMPK as a therapeutic target in renal cell carcinoma

Jennifer Woodard1, Sonali Joshi, Benoit Viollet

  • 1Robert H. Lurie Comprehensive Cancer Center and Division of Hematology-Oncology, Northwestern University Medical School and Jesse Brown VA Medical Center, Chicago, IL, USA.

Cancer Biology & Therapy
|October 16, 2010
PubMed

Insights

Activating AMPK (AMP-activated protein kinase) with AICAR or metformin inhibits renal cell carcinoma (RCC) growth. Combining these with statins enhances apoptosis, suggesting a new therapeutic strategy for RCC.

Area of Science:

  • Oncology
  • Molecular Biology
  • Biochemistry

Background:

  • The mTOR signaling pathway is crucial for cell growth and renal cell carcinoma (RCC) tumorigenesis.
  • AMPK (AMP-activated protein kinase) is a cellular energy sensor that negatively regulates mTOR.
  • Investigating AMPK's role in RCC offers potential therapeutic targets.

Purpose of the Study:

  • To determine if activating AMPK can inhibit the growth and survival of renal cell carcinoma (RCC) cells.
  • To explore the effects of AMPK activators, alone and in combination with statins, on RCC.
  • To elucidate the underlying molecular mechanisms involving mTOR inhibition.

Main Methods:

  • Activation of AMPK using AICAR (a known AMPK activator).
  • Treatment of RCC cells with AICAR, metformin, and statins, individually and in combination.
  • Assessment of cell growth, apoptosis, and anchorage-independent growth (tumorigenicity in vitro).
  • Analysis of mTOR pathway inhibition.

Main Results:

  • AICAR treatment potently suppressed RCC cell growth.
  • Combinations of AICAR or metformin with statins induced significant apoptosis in RCC cells.
  • AMPK activation led to the inhibition of mTOR and its downstream effectors.
  • AICAR and metformin, with or without statins, suppressed RCC anchorage-independent growth, indicating reduced tumorigenicity.

Conclusions:

  • AMPK activation plays a critical role in regulating the growth of renal cell carcinoma (RCC) cells.
  • AMPK activators, particularly in combination with statins, demonstrate potent anti-cancer effects against RCC.
  • These findings suggest a promising therapeutic strategy using AMPK activators for human renal cell carcinoma treatment.

More Related Videos

The Use of Reverse Phase Protein Arrays (RPPA) to Explore Protein Expression Variation within Individual Renal Cell Cancers12:22

The Use of Reverse Phase Protein Arrays (RPPA) to Explore Protein Expression Variation within Individual Renal Cell Cancers

Published on: January 22, 2013

Related Concept Videos

PI3K/mTOR/AKT Signaling Pathway01:22

PI3K/mTOR/AKT Signaling Pathway

The mammalian target of rapamycin  (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1  (mTORC1) and mTOR complex 2  (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast,  mTORC2 consists of a rapamycin-insensitive companion...
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
cAMP-dependent Protein Kinase Pathways01:25

cAMP-dependent Protein Kinase Pathways

Cyclic Adenosine Monophosphate (cAMP) is an essential second messenger that activates protein kinase A (PKA) and regulates various biological processes. A single epinephrine molecule binds to GPCR and activates several heterotrimeric G proteins, each stimulating multiple adenylyl cyclase, amplifying the signal, and synthesizing large numbers of cAMP molecules. Small changes in cAMP concentration affect PKA activity. The binding of four cAMP molecules induces a conformational change in PKA,...